Researchers from Biotiche Drug Discovery Srl and collaborators have discovered that modulating the activity of a specific family of potassium channels, known as Kv3 channels, can have beneficial effects on the progression of amyotrophic lateral sclerosis (ALS) in a mouse model of the disease. The study, published in the journal Acta Neuropathologica Communications, provides new insights into the role of these channels in skeletal muscle function and their potential as a therapeutic target for ALS.
Autifony Therapeutics Ltd. has described compounds acting as modulators of voltage-gated potassium channels from the Kv3 subfamily, such as Kv3.1, Kv3.2 and/or Kv3.3, reported to be useful for the treatment of myoclonic epilepsy, among others.
